GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Pre-Tax Income

CHRO (Chromocell Therapeutics) Pre-Tax Income : $-9.80 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Chromocell Therapeutics's pretax income for the three months ended in Jun. 2024 was $-1.77 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was $-9.80 Mil. Chromocell Therapeutics's pretax margin was %.

During the past 4 years, Chromocell Therapeutics's highest Pretax Margin was -330.50%. The lowest was -330.50%. And the median was -330.50%.


Chromocell Therapeutics Pre-Tax Income Historical Data

The historical data trend for Chromocell Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Pre-Tax Income Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
-0.66 -0.60 -2.46 -7.38

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -1.42 -4.04 -2.56 -1.77

Competitive Comparison of Chromocell Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Chromocell Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chromocell Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's Pre-Tax Income falls into.



Chromocell Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Chromocell Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-6.862+0+-0.519+0+0
=-7.38

Chromocell Therapeutics's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-1.764+0.004+-0.011+0+-0.0010000000000001
=-1.77

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics  (AMEX:CHRO) Pre-Tax Income Explanation

Chromocell Therapeutics's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-1.772/0
=%

During the past 4 years, Chromocell Therapeutics's highest Pretax Margin was -330.50%. The lowest was -330.50%. And the median was -330.50%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Chromocell Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired 08-07-2024